David Michael Williams, Executive Vice President and Chief Information & Digital Officer at Merck (NSE:PROR) & Co., Inc.

Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed ...

Co's stock has reached a 52-week low, dipping to $85.71. This downturn reflects a significant shift from the previous year, with the pharmaceutical giant experiencing a 1-year change of -31.59%.

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Upgrade your investment strategy with Merck using options and hedging to manage risk and seek gains in a volatile market. Learn more about MRK stock here.